Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a report released on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Price Performance

NASDAQ:EVGN opened at $1.80 on Tuesday. The company’s fifty day moving average price is $1.60 and its 200-day moving average price is $2.84. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40. The firm has a market capitalization of $9.67 million, a P/E ratio of -0.40 and a beta of 1.30.

Evogene (NASDAQ:EVGN) last issued its quarterly earnings data on Thursday, November 21st. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter. Evogene had a negative net margin of 314.43% and a negative return on equity of 109.05%.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new position in Evogene Ltd. (NASDAQ:EVGN) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. 10.40% of the stock is owned by hedge funds and other institutional investors.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.